Potential to play leading role in addressing Long COVID fatigue and muscle weakness via AXA1125’s mitochondrial and bioenergetic impact
Phase 2a clinical trial to be initiated by researchers at Oxford University by year-end; top-line data readout anticipated by mid-2022
Program to be discussed at Axcella’s R&D Day today at 10 a.m. EDT
A webcast of this event can be accessed by visiting the "Investors & News" section of the company’s website, www.axcellatx.com. A webcast replay will be available for 90 days following the presentation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.